Amy S Clark

14PUBLICATIONS
135CO-AUTHORS
Predictive and prognostic markersTumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Dec 09, 2025
Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors.

Mark Jesus M Magbanua, Nayelis A Manon, Denise M Wolf

|Sep 02, 2025
Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial.

Angela DeMichele, Amy S Clark, Emily Shea

|Jun 17, 2025
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.

Denise M Wolf, Christina Yau, Michael Campbell

|Apr 29, 2025
A Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor-Positive Breast Cancer: The BRACELET-01/PrE0113 Study.

Amy S Clark, Fengmin Zhao, Paula Klein

|Dec 18, 2023
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.

Kathy S Albain, Christina Yau, Emanuel F Petricoin

|Feb 28, 2023
Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B.

Amy S Clark, Fangxin Hong, Richard S Finn

Pageof 3

Frequent Collaborators

9 joint publications

Angela M DeMichele

6 joint publications

Laura van 't Veer

6 joint publications

Lamorna Brown-Swigart

6 joint publications

Gillian L Hirst